Clinical Microbiology and Immunology Department, National Liver Institute, Menoufia University, Shibin Elkom, 32511, Egypt.
Gastroenterology and Hepatology Department, National Liver Institute, Menoufia University, Shibin Elkom, 32511, Egypt.
Sci Rep. 2024 Sep 17;14(1):21687. doi: 10.1038/s41598-024-71102-1.
The aim of this study is to evaluate the role of serum level of Interleukin 6(IL-6) and Interleukin 17 (IL-17) in liver transplantation outcome for living recipients, Analyze the relation between the gene polymorphism and the occurrence of rejection after liver transplantation and Study the relation between the gene polymorphism and the occurrence of different infectious complications. The study was conducted in March 2023 and included 60 healthy volunteers from the National Liver Institute (NLI) blood bank at Menoufia University and 120 live donation liver recipient patients at NLI. During one month of liver transplantation, the cytokine levels (IL-17, IL-6 proteins, IL-6 G-174C, and IL-17 A rs2275913 gene polymorphism) and CD4 levels for 60 patients of 120 live donation liver recipient patients whom early reject transplanted tissue and the same parameters were measured after 6 months follow up for non-reject group. The main finding of this study was that the post-transplant rejection group and the post-transplant non-rejection and control groups differed significantly in the genotype frequency (CC, CG, and GG) or alleles of IL-6 G-174C (p = 0.011). On the other hand IL-17A rs2275913 gene polymorphism and its alleles (p = 0.71) showed no statistically significant difference. We also observed that serum IL-17 levels, with 100% specificity and 100% sensitivity threshold, will be more sensitive and specific than serum IL-6 and CD4 count in differentiating post-transplant rejection from non-rejection patients. The results showed that there was no significant relationship between the genotypes and serum levels of interleukins and the type and degree of rejection. Proinflammatory cytokines might be useful indicators for distinguishing and early identifying unfavorable outcomes after transplantation, allowing for prompt and effective treatment intervention. To evaluate these findings, prospective clinical trials are required.
本研究旨在评估白细胞介素 6 (IL-6) 和白细胞介素 17 (IL-17) 在活体受者肝移植结局中的作用，分析肝移植后排斥反应发生的基因多态性与基因多态性之间的关系，并研究基因多态性与不同感染性并发症发生的关系。该研究于 2023 年 3 月进行，纳入了来自梅努菲亚大学国家肝脏研究所 (NLI) 血库的 60 名健康志愿者和 NLI 的 120 名活体供肝移植受者。在肝移植后的一个月内，测量了 120 名活体供肝移植受者中 60 名早期排斥移植组织的患者的细胞因子水平 (IL-17、IL-6 蛋白、IL-6 G-174C 和 IL-17A rs2275913 基因多态性) 和 CD4 水平，并在 6 个月的非排斥组随访后测量了相同的参数。本研究的主要发现是，移植后排斥组和移植后非排斥组与对照组在 IL-6 G-174C 的基因型频率 (CC、CG 和 GG) 或等位基因 (p = 0.011) 上有显著差异。另一方面，IL-17A rs2275913 基因多态性及其等位基因 (p = 0.71) 无统计学差异。我们还观察到，血清 IL-17 水平具有 100%特异性和 100%敏感性阈值，在区分移植后排斥和非排斥患者方面将比血清 IL-6 和 CD4 计数更敏感和特异。结果表明，基因型与白细胞介素血清水平之间、白细胞介素与排斥类型和程度之间均无显著关系。促炎细胞因子可能是区分移植后不良结局和早期识别的有用指标，从而可以及时有效地进行治疗干预。需要进行前瞻性临床试验来评估这些发现。
